Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease

Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and can lead to life-threatening complications like hepatic carcinoma and cirrhosis. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic drug, has the capacity to overcome insulin...

Full description

Bibliographic Details
Main Authors: Shan Li, Xiaoman Wang, Jielei Zhang, Jingyi Li, Xiaogang Liu, Yuanyuan Ma, Chao Han, Lixia Zhang, Lili Zheng
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2018-06-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
GLP-1
FTO
NAFLD
PI3K
Hepatic steatosis
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000800612&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000800612&lng=en&tlng=en

Similar Items